Nicolas Goossens

All things liver, especially steatotic liver disease. Hepatologist, clinician and translational research from #Geneva, #Switzerland.

[Nicolas Goossens @NicoGooss]

The liver isn't just for metabolism and detox—it's a biological compass! 🧭
@ScienceMagazine reveals that homing pigeons rely on magnetic liver macrophages to navigate.

How cool is this?? 🐦🧲

#Hepatology #Liver #Science

https://t.co/vfk4L38YOT

[NEJM @NEJM]

Should we hold GLP-1–based medications before upper endoscopy?

@NEJMClinician Editor-in-Chief Raja-Elie Abdulnour, MD (@BageLeMage), explains a trial that evaluated the clinical impact of continuing vs holding GLP-1–based medications prior to upper endoscopy. Read the key results and comment from Sara Turbow, MD, MPH: https://t.co/aZlEXFf6NY

Visit https://t.co/CgkwvhdPaG to see What Matters Most This Week, including:

🗣️ Does Your Patient Have Laryngopharyngeal Symptoms, or Laryngopharyngeal Reflux Disease?
🫁 Comparing Dual Bronchodilators for COPD
💊 Progestin-Only Contraception and Venous Thromboembolism Risk
🫀 Does Ciprofloxacin Really Prolong QT Intervals?

[Gastro Hep Advances @AGA_GHAdvances]

A screening trade-off in MASLD - The EASL/AASLD strategy has ⬆️ specificity but ⬇️ sensitivity for detecting significant fibrosis. ➡️ Missed opportunities for early intervention?
🔗 https://t.co/DE6pOu52rP
👨‍⚕️@NicoGoos

[NEJM @NEJM]

The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which Drs. Laurent Castera, Mary E. Rinella, and Emmanuel A. Tsochatzis review. Learn more: https://t.co/oZ93UDdEiA

[The Lancet @TheLancet]

The global burden of liver cancer is increasing, with new cases set to double by 2050.

On the cover, the latest Commission report on addressing the global hepatocellular carcinoma burden.

This and more in our latest issue 👉 https://t.co/GbLi5Fw6BF

[Salvador Benlloch @doctorbenlloch]

📢Interprofessional teams 🤝🙌🤝in patients with diabetes and MASLD: management, and liver monitoring
ADA Consensus Report 2025.
Open: 👉https://t.co/iStdP5AXwL
@AEEHLiver @sociedadSEEN @AmDiabetesAssn #FattyLiver #DiabetesAwareness #NAFLD

[euan ashley @euanashley]

Atul Butte died yesterday.
The world lost a giant.
A big bear of a man.
With a huge smile.
With love for everyone.
With energy that could power a room.
I loved everything about Atul.
I loved how he was always happy.
I loved how excited he was about science and helping people.

[Nicolas Goossens @NicoGooss]

@rabataller Superb pictures!

[Bruno Ramos-Molina, PhD @Brunorm84]

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis #MASH @NatRevDrugDisc https://t.co/8TF2qpxMNc

[Elliot Tapper @ebtapper]

How to resmetirom

Practice guidelines from @AASLDtweets led by @MichiganLiver’s own Vincent Chen

Open access: https://t.co/LFgaYXwhWu

[Journal of Hepatology @JHepatology]

🆕REVIEW❕

Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board

#OpenAccess here👉https://t.co/3fyR1KqZA6

#LiverTwitter

[EASO @EASOobesity]

@EASOobesity has published an important paper in @NatureMedicine outlining an updated framework for diagnosing, staging, and managing obesity in adults, emphasising obesity as an adiposity based chronic disease #ABCD

Learn more: https://t.co/6yaHEdsYPL

@WorldObesity

[Bruno Ramos-Molina, PhD @Brunorm84]

Liver ACOX1 regulates levels of circulating lipids that promote metabolic health through adipose remodeling @NatureComms https://t.co/vzJVE5IuZv

[roypounder.apt @APandT]

"Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures" now free to read at https://t.co/L63FmCQyky

[Gene Im @geneyim]

Excited for this newly announced Phase 2 trial of GLP-1s for AUD in patients with ALD by @novonordiskus.

Clinical trials for this highly prevalent, at-risk group of patients are so rare! and desperately needed.

We need more R&D but this is a great start.

[HUG @hug_ge]

Zoom sur le Centre des affections hépatobiliaires et pancréatiques dirigé par le Dr Nicolas Goossens et la Dre Aurélie Bornand: https://t.co/NwQo84AVBI #médecine #gastroentérologie #hépatologie #transplantation

[Nicolas Goossens @NicoGooss]

If you want to learn about congenital portosystemic shunts (CPSS), read this fantastic review in @JHEP_Reports from the leading experts in the field.

https://t.co/3qw8APj11E

[HUG @hug_ge]

Les HUG ont organisé la première journée de dépistage de la fibrose du foie. Le Dr Nicolas Goossens parle de cette maladie souvent méconnue mais pouvant entraîner des pathologies graves : https://t.co/LiC9pvgzLN @NicoGooss #dépistage #foie #santé

[The BMJ @bmj_latest]

Why do we need to evaluate prediction models?

This article, the first in a three part series, explains @GSCollins
https://t.co/7rVghU4PDk

[Jean-Charles Nault @NaultJc]

Illusory generalizability of clinical prediction models | Science https://t.co/t9yKuwCDap